文献速递遗传性与小管间质肾病

谷氨酰胺酶1介导的谷氨酰胺代谢在常染色体显性多囊肾病中的作用

Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究探讨谷氨酰胺酶1(GLS1)在常染色体显性多囊肾病(ADPKD)囊肿生长中的作用。体外实验显示GLS1抑制剂BPTES和CB-839可阻断forskolin诱导的囊肿形成;体内实验中CB-839在Aqp2-Cre;Pkd1fl/fl小鼠中减缓囊肿生长,但在Pkhd1-Cre;Pkd1fl/fl小鼠中无效,且对mTOR和MEK活化的抑制效果不同。结论提示谷氨酰胺代谢改变可能参与囊肿生长,但GLS1作为药物靶点需进一步验证。

要点

  • GLS1-GAC亚型在ADPKD患者囊肿衬里上皮和鼠标模型中上调。
  • BPTES和CB-839在体外阻断forskolin诱导的囊肿形成。
  • CB-839在Aqp2-Cre;Pkd1fl/fl小鼠中减缓囊肿生长,但在Pkhd1-Cre;Pkd1fl/fl小鼠中无效。

核心结论

  • 谷氨酰胺代谢改变可能参与ADPKD囊肿生长,但GLS1抑制效果因模型而异,需进一步验证其作为药物靶点的价值。

研究设计与样本

  • 体外培养正常人类肾脏和ADPKD人类囊肿衬里上皮细胞,使用GLS1抑制剂BPTES和CB-839处理,评估增殖、胶原中囊肿生长及下游信号通路活化。
  • 体内使用CB-839抑制GLS1,在Aqp2-Cre;Pkd1fl/fl和Pkhd1-Cre;Pkd1fl/fl两种ADPKD小鼠模型中观察囊肿生长。

主要发现

  • GLS1-GAC亚型在人类ADPKD肾脏囊肿衬里上皮和ADPKD小鼠模型中表达上调。
  • BPTES和CB-839在体外阻断forskolin诱导的囊肿形成。
  • CB-839在Aqp2-Cre;Pkd1fl/fl小鼠中减缓囊肿生长,但在Pkhd1-Cre;Pkd1fl/fl小鼠中未减缓。
  • CB-839抑制Aqp2-Cre;Pkd1fl/fl小鼠中的mTOR和MEK活化,但在Pkhd1-Cre;Pkd1fl/fl小鼠中未抑制。

临床怎么用

  • GLS1抑制在ADPKD中的疗效可能依赖于遗传背景或疾病模型,临床转化前需明确适用人群。
  • 未来需在其他PKD模型中测试并鉴定 bypass GLS1抑制的代偿性代谢变化,以验证GLS1作为单药或联合靶点的可行性。

局限性

  • GLS1抑制在两种小鼠模型中效果不一致,提示模型特异性差异。
  • 未鉴定代偿性代谢变化,GLS1作为药物靶点需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolism of glutamine by glutaminase 1 (GLS1) plays a key role in tumor cell proliferation via the generation of ATP and intermediates required for macromolecular synthesis. We hypothesized that glutamine metabolism also plays a role in proliferation of autosomal-dominant polycystic kidney disease (ADPKD) cells and that inhibiting GLS1 could slow cyst growth in animal models of ADPKD. METHODS: Primary normal human kidney and ADPKD human cyst-lining epithelial cells were cultured in the presence or absence of two pharmacologic inhibitors of GLS1, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) and CB-839, and the effect on proliferation, cyst growth in collagen and activation of downstream signaling pathways were assessed. We then determined if inhibiting GLS1 in vivo with CB-839 in the Aqp2-Cre; Pkd1fl/fl and Pkhd1-Cre; Pkd1fl/fl mouse models of ADPKD slowed cyst growth. RESULTS: We found that an isoform of GLS1 (GLS1-GAC) is upregulated in cyst-lining epithelia in human ADPKD kidneys and in mouse models of ADPKD. Both BPTES and CB-839 blocked forskolin-induced cyst formation in vitro. Inhibiting GLS1 in vivo with CB-839 led to variable outcomes in two mouse models of ADPKD. CB-839 slowed cyst growth in Aqp2-Cre; Pkd1fl/fl mice, but not in Pkhd1-Cre; Pkd1fl/fl mice. While CB-839 inhibited mammalian target of rapamycin (mTOR) and MEK activation in Aqp2-Cre; Pkd1fl/fl, it did not in Pkhd1-Cre; Pkd1fl/fl mice. CONCLUSION: These findings provide support that alteration in glutamine metabolism may play a role in cyst growth. However, testing in other models of PKD and identification of the compensatory metabolic changes that bypass GLS1 inhibition will be critical to validate GLS1 as a drug target either alone or when combined with inhibitors of other metabolic pathways.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Soomro I, Sun Y, Li Z, et al. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2018. PMID: 29420817. doi:10.1093/ndt/gfx349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。